Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and... see more

TSX:ONC - Post Discussion

Oncolytics Biotech Inc > My Summary of Cantor Fitzgerald Zoom Call 19 May
View:
Post by askretka on May 19, 2023 8:23pm

My Summary of Cantor Fitzgerald Zoom Call 19 May

Extremely busy day for me personally but here's my summary anyway .
 
 
I forgot about call but got a pop up warning on my phone so wasn't really set up to get all the info properly. I did buy more shares based on what I heard though. 
 
People attending were:
 
1. Dr. Diamond Oncology specialist I can't remember his first name unfortunately.
 
2. Louise Chen. Cantor Fitzgerald. 
 
 3. Another Cantor Fitzgerald analyst. 
 
Main question the other CF analyst asked "loaded question" as he put it. Was on Oncolytics Biotech and what can we expect at ATCO on Breast cancer. 
 
He said basically that if this study repeats as well as previous results. It should be quite promising. ( I'm assuming IND-213 and AWARE-1)
 
"Need a good response rate not necessarily a dramatic one and that if 
response rates hold up to what we've already seen."
 
"That that would be ' Stupendous' " and that nothing could compete with them. "
 
Went through 4 companies that Cantor Fitzgerald follows.
 
1. Replimmune:  modified Herpes virus
 
Rp1 Rp2 Rp3 . Interesting he said that Rp3 is most modified virus and as you continue to modify it can cause problems? He seem to prefer Rp1 as most promising?
 
2. Transgene:  Has made strides in head and neck cancer. Most advanced  virus in testing is TG4001.
They are working with an AI company NEC. Picking out neoantigens. Sounded promising.
 
3. Genelux: Vaccina virus. In phase 3 Ovarian Cancer
Tough space. Lots of resistance develops to treatments. Just stable disease won't cut it here. Need PFS or OS to proceed.
 
4. Oncolytics Biotech: See above. and he said if results are good in breast cancer it could justify using  earlier in 
treatment cycle as the immune system is beat up by chemotherapy and other treatments. 
 
? First line treatment combos??
 
Some other general questions the expert was asked was what cancers would OV's be good for?
 
Answer: Cancers where CI'S don't work well. Cold Tumors.  Breast Cancer. Colon Cancer MSI low group.
And " The scourge of mankind " PANCREATIC CANCER. 
 
I'm sure I missed a few minor details but this is what I have from notes I typed and my  memory.
Cheers!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
 
 
 
 
 
 
 
 
 
 
 
 
Comment by fasttrack5 on May 19, 2023 8:55pm
Thanks for your info Askretka obviously exciting times for ONC
Comment by inthno on May 19, 2023 10:20pm
Hello and thanks for the update as I was out of the country. May I ask who was answering the questions in respect to onc. We really need a win at this point and jot a all we need now is to wait for this or that as if it is good here then really should work in crc or so I am thinking. No more delays and time to move this forward hard and fast.
Comment by askretka on May 20, 2023 2:12am
Dr. Diamond was the Oncology specialist answering the questions from the two Cantor Fitzgerald analysts.  Cheers!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities